Advancing healthcare through personalized medicine

183 Pages·2017·2.48 MB·English

by  Hays, Priya

Advancing
Healthcare Through
Personalized Medicine
Advancing
Healthcare Through
Personalized Medicine
Priya Hays, PhD
Cepheid Corporation
Sunnyvale, CA
CRC Press
Taylor & Francis Group
6000 Broken Sound Parkway NW, Suite 300
Boca Raton, FL 33487-2742
© 2017 by Taylor & Francis Group, LLC
CRC Press is an imprint of Taylor & Francis Group, an Informa business
No claim to original U.S. Government works
Printed on acid-free paper
International Standard Book Number-13: 978-1-4987-6708-8 (Paperback)
This book contains information obtained from authentic and highly regarded sources. While all reasonable efforts have
been made to publish reliable data and information, neither the author[s] nor the publisher can accept any legal respon-
sibility or liability for any errors or omissions that may be made. The publishers wish to make clear that any views or
opinions expressed in this book by individual editors, authors or contributors are personal to them and do not neces-
sarily reflect the views/opinions of the publishers. The information or guidance contained in this book is intended for
use by medical, scientific or health-care professionals and is provided strictly as a supplement to the medical or other
professional’s own judgement, their knowledge of the patient’s medical history, relevant manufacturer’s instructions and
the appropriate best practice guidelines. Because of the rapid advances in medical science, any information or advice
on dosages, procedures or diagnoses should be independently verified. The reader is strongly urged to consult the drug
companies’ printed instructions, and their websites, before administering any of the drugs recommended in this book.
This book does not indicate whether a particular treatment is appropriate or suitable for a particular individual. Ulti-
mately it is the sole responsibility of the medical professional to make his or her own professional judgements, so as to
advise and treat patients appropriately. The authors and publishers have also attempted to trace the copyright holders of
all material reproduced in this publication and apologize to copyright holders if permission to publish in this form has
not been obtained. If any copyright material has not been acknowledged please write and let us know so we may rectify
in any future reprint.
Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmitted, or uti-
lized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopy-
ing, microfilming, and recording, or in any information storage or retrieval system, without written permission from the
publishers.
For permission to photocopy or use material electronically from this work, please access www.copyright.com (http://
www.copyright.com/) or contact the Copyright Clearance Center, Inc. (CCC), 222 Rosewood Drive, Danvers, MA 01923,
978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For
organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged.
Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for iden-
tification and explanation without intent to infringe.
Visit the Taylor & Francis Web site at
http://www.taylorandfrancis.com
and the CRC Press Web site at
http://www.crcpress.com
For Shreyas, Tejas, Sahil, and Rohan
Four Treasures
Contents
Preface xi
Acknowledgments xiii
1 Introduction: Biomedical inovation and policy in the twenty-frst century 1
Chalenges and incentives for implementation 10
Components of the bok 10
References 12
2 The rise of genomics and personalized medicine 13
Human genome project, sequencing, and genomic data 13
ENCODE: Maping the functional genome 16
Next-generation sequencing and multigene aproaches 16
Pharmacogenetics–pharmacogenomics 17
CYP2D6 20
Pharmacogenomics of warfarin 20
UDP-glucoronyltransferase 2
Pharmacogenetics and HIV, abacavir, and HLA-B*5701 23
Emergence of personalized medicine 23
Biomarker discovery 25
References 26
3 Patient naratives: Personalized medicine in the feld 29
4 Aliances: Knowledge infrastructures and precision medicine 37
Precision medicine: Its potential development and implementation 37
Implications of precision medicine for patient care and disease treatment 40
Macroeconomic considerations of precision medicine 43
Global aliance for genomics and health 45
References 48
5 Great strides in precision medicine: Personalized oncology and molecular diagnostics 49
Cancer care 53
Oncogenesis 53
Molecular abnormalities in solid tumors 53
Tumor subtypes 5
Breast cancer 5
Incidence and mortality 5
Inherited breast cancer 5
Curent breast cancer diagnosis standards 56
MamaPrint 56
Veridex Roterdam signature 76 genes 56
vii
viii Contents
Prosigna, PAM50-based signature 57
Conclusions 57
Colorectal cancer 57
Incidence and mortality 57
Molecular pathology and diagnostics of colorectal cancer 58
Inherited CRC syndrome 58
Hereditary nonpolyposis colorectal carcinoma (Lynch syndrome) 58
De novo colorectal cancer 58
Melanoma 59
Incidence and mortality 59
Lung cancer 60
Incidence and mortality 60
Molecular diagnosis 65
Prostate cancer 65
Incidence and mortality 65
Brain cancers 66
Incidence and mortality 66
Molecular classifcation of glioblastoma 67
Tumor immunology 67
Hematologic malignancies 68
Incidence and mortality 68
Trends in personalized oncology 70
MicroRNAs 70
Liquid biopsies 71
Immunotherapy 72
Systems biology 73
Cancer vaccines 74
Conclusion 76
References 77
6 Personalized medicine’s impact on disease 79
Type II diabetes 79
Rheumatoid arthritis 80
Multiple sclerosis 81
Cardiovascular disease 81
Clopidogrel pharmacogenetics 83
Warfarin pharmacogenetics 84
CYP2C9 85
VKORC1 85
AIDS 86
Psychiatry 86
Major depressive disorder and bipolar disorder 88
Alterations in drug-metabolizing enzymes 88
Predictors of treatment response 88
Pharmacogenetics of schizophrenia 89
Antipsychotic response 89
Antipsychotic-induced side effects 90
Conclusion 90
References 91
7 The genome in the clinic: Diagnosis, treatment, and education 93
Companion diagnostics: “Omics” and the translation of biomarker
discoveries into routine diagnostics 94
Contents ix
Emerging personalized medicine in disease: Diagnostic tests, biomarkers, and targeted
treatments 97
Cardiovascular disease 97
Hypertension 98
Mental health 98
Thyroid cancer 9
Breast cancer 9
Colorectal cancer 10
HIV 10
Implementation of personalized diagnosis and treatment: Educating patients and
healthcare providers 10
References 102
8 A new set of clinical tols for physicians 103
Precision medicine in community healthcare setings 103
Genomic healthcare team 104
Diagnostic odysey 106
Personalized healthcare 108
Finding variants of signifcance in clinics and sequencing centers 109
References 10
9 The regulatory landscape 1
Laboratory-developed tests 12
Analyte-specifc reagents 13
Clinical laboratory improvement amendments 13
Chalenges of medical device framework for NGS 14
FDA pharmacogenomics drug labeling 14
References 15
10 Translational personalized medicine: Molecular profling, druggable targets, and clinical
genomic medicine 17
Basic research 120
Drugable genome 120
GWAS and the international HapMap project 121
Clinical biomarker discovery and somatic mutations 122
Alzheimer’s disease 123
Atherosclerosis and cardiovascular risk 123
Colorectal cancer 123
Translational medicine and technology 124
Conclusions 132
References 132
1 The economics of personalized medicine 13
Establishing value for molecular diagnostic tests 136
Payer perspective 137
Personalized medicine and pharmacogenomics: From micro to macro 141
References 14
12 Moral and ethical issues: Claims, consequences, and caveats 145
Ethics of personalized medicine 148
References 153
Conclusion 15
Index 159